A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10–60 Years Following Essen and Zagreb Vaccination Procedures

Objective: In this paper, we aim to show that the immunogenicity of the lyophilized human rabies vaccine (Vero cells) (investigational vaccine) developed by Dalian Aleph Biomedical Co., Ltd. in healthy participants aged 10–60 years old is non-inferior to the lyophilized PVRV (positive control) manuf...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaohong, Li, Jia, Zhou, Lei, Chen, Jianmin, Jin, Zhongqiang, Meng, Qingwei, Chai, Jing, Gao, Hongxia, Wang, Yunpeng, Zhao, Danhua, Wu, Heng, Yu, Jieran, Chen, Nan, Wang, Yanan, Lin, Yuan, Huang, Peifang, Li, Yuhua, Zhang, Yuhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458047/
https://www.ncbi.nlm.nih.gov/pubmed/37631879
http://dx.doi.org/10.3390/vaccines11081311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458047/
https://www.ncbi.nlm.nih.gov/pubmed/37631879
http://dx.doi.org/10.3390/vaccines11081311

Ejemplares similares